D&D Pharmatech (347850.KQ)

KRW 47200.0

(0.21%)

Total Debt Summary of D&D Pharmatech

  • D&D Pharmatech's latest annual total debt in 2023 was 8.13 Billion KRW , down -70.13% from previous year.
  • D&D Pharmatech's latest quarterly total debt in 2024 Q2 was 8.03 Billion KRW , down 0.0% from previous quarter.
  • D&D Pharmatech reported annual total debt of 27.23 Billion KRW in 2022, down -37.5% from previous year.
  • D&D Pharmatech reported annual total debt of 43.57 Billion KRW in 2021, up 660.46% from previous year.
  • D&D Pharmatech reported quarterly total debt of 8.03 Billion KRW for 2024 Q2, down 0.0% from previous quarter.
  • D&D Pharmatech reported quarterly total debt of - KRW for 2023 Q1, down -100.0% from previous quarter.

Annual Total Debt Chart of D&D Pharmatech (2023 - 2019)

Historical Annual Total Debt of D&D Pharmatech (2023 - 2019)

Year Total Debt Total Debt Growth
2023 8.13 Billion KRW -70.13%
2022 27.23 Billion KRW -37.5%
2021 43.57 Billion KRW 660.46%
2020 5.73 Billion KRW 196.85%
2019 1.93 Billion KRW 0.0%

Peer Total Debt Comparison of D&D Pharmatech

Name Total Debt Total Debt Difference
HLB Co., Ltd. 62.7 Billion KRW 87.028%
iNtRON Biotechnology, Inc. 402.9 Million KRW -1918.891%
BINEX Co., Ltd. 53.5 Billion KRW 84.798%
Bioneer Corporation 44.63 Billion KRW 81.778%
Anterogen.Co.,Ltd. 9.74 Billion KRW 16.489%
MEDIPOST Co., Ltd. 52.33 Billion KRW 84.458%
CrystalGenomics, Inc. 32 Billion USD 74.583%
Helixmith Co., Ltd 20.22 Billion KRW 59.786%
Chabiotech Co.,Ltd. 449.63 Billion KRW 98.191%
Medy-Tox Inc. 82.83 Billion KRW 90.18%
Peptron, Inc. 9.13 Billion KRW 10.935%
Amicogen, Inc. 149.59 Billion KRW 94.562%
Genexine, Inc. 67.42 Billion KRW 87.936%
HLB Therapeutics Co.,Ltd. 10.02 Billion KRW 18.838%
LegoChem Biosciences, Inc. 12.64 Billion KRW 35.666%
ALTEOGEN Inc. 83.76 Billion KRW 90.29%
PharmaResearch Co., Ltd. 34.3 Billion KRW 76.289%
SillaJen, Inc. 9.69 Billion KRW 16.112%
JETEMA, Co., Ltd. 130.49 Billion KRW 93.767%
OliX Pharmaceuticals,Inc 39.35 Billion KRW 79.332%
Genomictree Inc. 1.83 Billion KRW -343.369%
MedPacto, Inc. 8.6 Billion KRW 5.46%
EASY BIO,Inc. 82.27 Billion KRW 90.114%
GI Innovation, Inc. 3.72 Billion KRW -118.615%